Retatrutide is an investigational triple agonist for the GIP, GLP-1, and glucagon receptors, a mechanism that combines appetite suppression with increased energy expenditure. This multi-pathway approach has demonstrated unprecedented levels of weight loss and improvement in metabolic markers like insulin sensitivity and liver fat in clinical trials. Its healthspan relevance lies in its potential to powerfully reverse metabolic syndrome, a key accelerator of multiple age-related diseases.
Verdict
A potentially game-changing metabolic intervention, pending final trial data and approval.
HEALTHSPAN IMPACT
Foundational
RISK LEVEL
High
EVIDENCE GRADE
B
MONTHLY COST
$0 - $0
Protocol
- Currently investigational; clinical trials are evaluating weekly subcutaneous injections from 1 mg to 12 mg.
Flags
- Currently an investigational drug and not approved for public use.
- Common side effects include nausea, diarrhea, and vomiting, especially during dose escalation.
- Potential for interactions with other medications affecting gastric emptying or blood sugar.
- Long-term safety profile beyond clinical trial duration is unknown.